丹参多酚酸盐注射液联合常规治疗心绞痛的系统评价与Meta分析
结果显示联合治疗在改善心绞痛症状、心电图及减少硝酸甘油用量方面优于单用常规治疗,但因方法学质量低、存在发表偏倚及缺乏重要临床结局,结论需谨慎解读。
要点
- 丹参多酚酸盐注射液联合常规治疗可改善心绞痛症状(RR=1.28)。
- 联合治疗可提高心电图改善率(RR=1.32)并减少硝酸甘油用量(RR=1.50)。
- 纳入试验方法学质量低且存在发表偏倚,结论需谨慎解读。
核心结论
- 丹参多酚酸盐注射液联合常规治疗心绞痛患者可能有效,但因方法学质量低、发表偏倚及缺乏重要临床结局,结论需谨慎解读。
研究设计与样本
- 采用Cochrane偏倚风险工具和CONSORT for traditional Chinese medicine评价方法学与报告质量,用RevMan 5.3软件进行Meta分析。
主要发现
- 联合治疗改善心绞痛症状优于单用常规治疗(RR=1.28,95% CI 1.24至1.31,p<0.00001)。
- 联合治疗减少心绞痛发作频率(次/周)(WMD=-1.47,95% CI -2.16至-0.78)。
- 联合治疗降低临床证候积分(WMD=-0.55,95% CI -0.57至-0.53,p<0.000011),提高躯体受限评分(WMD=7.68,95% CI 1.48至13.88,p=0.02)。
- 联合治疗改善心电图(RR=1.32,95% CI 1.27至1.38,p<0.00001)并减少硝酸甘油用量(RR=1.50,95% CI 1.26至1.77,p<0.00001)。
- Egger回归检验提示存在发表偏倚(Kendall tau=0.36,p<0.01),且无试验报告冠心病死亡率或冠心病事件率。
临床怎么用
- 在常规治疗基础上可考虑联合丹参多酚酸盐注射液以改善心绞痛症状和心电图,但需结合患者具体情况并关注不良反应报告不足的问题。
局限性
- 多数试验因方法学报告不佳被归为偏倚风险不明确,整体方法学质量低。
- 存在发表偏倚(Kendall tau=0.36,p<0.01)。
- 缺乏冠心病死亡率或冠心病事件率等重要临床结局,且不良事件报告不充分。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Currently, many trials have been conducted to investigate the beneficial and harmful effects of Salvia miltiorrhiza depside salts for infusion for treating patients with angina pectoris. It is important to systematically and criticallyevaluate the existing literature into providing a pooled effect to examine outcomes of angina pectoris with Salvia miltiorrhiza depside salts for infusion. PURPOSE: A systematic review and meta-analysis were performed to determine the clinical curative effect and safety of Salvia miltiorrhiza depside salts for infusion for angina pectoris and provide clear evidence to inform clinical practice. METHOD: The Cochrane Library, MEDLINE, EMBASE, and other four electronic Chinese databases were searched to identify relevant randomized controlled trials. Methodological quality and reporting quality of eligible studies was evaluated by using the Cochrane risk-of-bias tool and CONSORT for traditional Chinese medicine respectively. Meta-analysis was performed by RevMan 5.3 software. RESULT: Fifty-six randomized controlled trials involving 5503 patients were included. Most of the trials were classified as having an unclear risk of bias because of poor reported methodology. The main outcomes are improvements in angina symptoms, ECG improvement and reduction of nitroglycerin use. CHD mortality or rate of CHD events was not reported in any trial. Meta-analysis showed that Salvia miltiorrhiza depside salts for infusion combined with conventional treatment was better than conventional treatment alone in improving angina symptoms (RR= 1.28, 95% CI 1.24 to 1.31, p < 0.00001), the frequency of angina attack (time/week)(WMD=-1.47, 95% CI -2.16 to -0.78), reducing clinical symptom scores (WMD=-0.55, 95% CI -0.57 to -0.53, p < 0.000011), increasing physical limitation scores (WMD= 7.68, 95% CI 1.48 to 13.88, p = 0.02), improving ECG (RR= 1.32,95% CI 1.27 to 1.38, p < 0.00001) and reducing dosage of nitroglycerin (RR= 1.50, 95% CI: 1.26 to 1.77, p < 0.00001). In addition, Egger's regression tests was found there was publication bias (Kendall' tau= 0.36, p < 0.01). CONCLUSION: The current systematic review indicates relevant evidence for Salvia miltiorrhiza depside salts for infusion combined with conventional treatments treating patient with angina pectoris. However, the results should be interpreted with caution due to the low methodological quality, the risk of publication bias, lack of important clinically relevant outcomes and inadequate reporting on adverse events of the included trials. International methodological and reporting standards could help researchers conduct well designed trials and generate better evidence for Salvia miltiorrhiza depside salts for infusion.
引用
- Zhang Y, Xie Y, Liao X, et al. A Chinese patent medicine Salvia miltiorrhiza depside salts for infusion combined with conventional treatment for patients with angina pectoris: A systematic review and meta-analysis of randomized controlled trials. Phytomedicine. 2017. PMID: 28190464. doi:10.1016/j.phymed.2017.01.002
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。